{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,9]],"date-time":"2026-11-09T22:49:26Z","timestamp":1794264566217,"version":"4.9.0"},"reference-count":42,"publisher":"Wiley","issue":"4","license":[{"start":{"date-parts":[[2012,2,7]],"date-time":"2012-02-07T00:00:00Z","timestamp":1328572800000},"content-version":"vor","delay-in-days":6,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":["bjui-journals.onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["BJU International"],"published-print":{"date-parts":[[2012,2]]},"abstract":"<jats:p>\n                    <jats:bold>What's known on the subject? and What does the study add?<\/jats:bold>\n                  <\/jats:p>\n                  <jats:p>The standard treatment for non\u2010muscle invasive bladder (NMIBC) is transurethral resection followed by intravesical therapy. Intravesical agents, e.g. bacille Calmette\u2010Gu\u00e9rin (BCG) or mitomycin C (MMC), have activity in delaying and reducing the incidence of tumour recurrence after surgery but have significant side\u2010effects and are not effective in all patients. Clinical data suggests that gemcitabine has activity in this disease in terms of tumour response and is less toxic, and warrants further study.<\/jats:p>\n                  <jats:p>This systematic review comprehensively presents the available clinical evidence on intravesical gemcitabine for NMIBC. The limited data from randomised trials suggest that gemcitabine may have role in intermediate\u2010risk patients, as an alternative to MMC, and in high\u2010risk, BCG\u2010refractory patients. Data from observational studies indicate that minimal systemic absorption occurs with intravesical administration and that gemcitabine is active in reducing tumour recurrence.<\/jats:p>\n                  <jats:p>\n                    <jats:list list-type=\"explicit-label\">\n                      <jats:list-item>\n                        <jats:p>Intravesical immunotherapy or chemotherapy for non\u2010muscle invasive bladder cancer is a well\u2010established treatment for preventing or delaying tumour recurrence after tumour resection. However, up to 70% of patients may fail and new intravesical agents with improved effectiveness are needed. Gemcitabine is a relatively new anticancer drug that has shown activity against bladder cancer.<\/jats:p>\n                      <\/jats:list-item>\n                      <jats:list-item>\n                        <jats:p>To systematically review the literature on the effectiveness and toxicity of intravesical gemcitabine for non\u2010muscle invasive bladder cancer (NMIBC).<\/jats:p>\n                      <\/jats:list-item>\n                      <jats:list-item>\n                        <jats:p>MEDLINE, EMBASE, CINAHL, the Cochrane database of systematic reviews, LILACS, SCOPUS, BNI, Biomed Central, Web of Science and BIOSIS were searched to identify trials of intravesical gemcitabine for the treatment of NMIBC. Also searched were meeting proceedings, international guidelines and trial registries. Data on authors, study design, patient characteristics, interventions and outcome data relating to tumour recurrence, disease progression, survival and adverse events were extracted from relevant studies.<\/jats:p>\n                      <\/jats:list-item>\n                      <jats:list-item>\n                        <jats:p>Six relevant randomised trials were identified with the number of patients randomised in each trial varying from 30 to 341 (total 704). All trials compared gemcitabine to active controls and varied in the reporting of outcomes.<\/jats:p>\n                      <\/jats:list-item>\n                      <jats:list-item>\n                        <jats:p>The first was a marker lesion study which reported greater tumour response rates when intravesical gemcitabine (2\u2003g) was given as three bi\u2010weekly doses (36%) or six weekly doses (40%) compared with a single dose (9%).<\/jats:p>\n                      <\/jats:list-item>\n                      <jats:list-item>\n                        <jats:p>\n                          One study compared a single postoperative instillation of intravesical gemcitabine with a saline placebo in 341 patients and found no significant difference in the rates of tumour recurrence (28% vs 39%, respectively) or recurrence\u2010free survival (hazard ratio 0.95, 95% confidence interval 0.64\u20131.39,\n                          <jats:italic>P<\/jats:italic>\n                          = 0.77). The rate of progression to invasive disease was greater with gemcitabine (2.4% vs 0.8%).\n                        <\/jats:p>\n                      <\/jats:list-item>\n                      <jats:list-item>\n                        <jats:p>\n                          A further trial compared gemcitabine with intravesical mitomycin C (MMC) and reported that the rates of recurrence (28% vs 39%) and progression (11% vs 18%) were lower with gemcitabine but did not reach statistical significance. The overall incidence of adverse events was significantly less with gemcitabine (38.8% vs 72.2%,\n                          <jats:italic>P<\/jats:italic>\n                          = 0.02).\n                        <\/jats:p>\n                      <\/jats:list-item>\n                      <jats:list-item>\n                        <jats:p>Three trials compared gemcitabine with intravesical bacille Calmette\u2010Gu\u00e9rin (BCG) but a meta\u2010analysis was not possible due to clinical heterogeneity.<\/jats:p>\n                      <\/jats:list-item>\n                      <jats:list-item>\n                        <jats:p>\n                          In untreated patients at intermediate risk of recurrence (primary Ta\u2013T1, no carcinoma\n                          <jats:italic>in situ<\/jats:italic>\n                          ) one trial showed that gemcitabine and BCG were similar with respective recurrence rates of 25% and 30% (\n                          <jats:italic>P<\/jats:italic>\n                          = 0.92) and overall progression equal. Dysuria (12.5% vs 45%,\n                          <jats:italic>P<\/jats:italic>\n                          &lt; 0.05) and frequency (10% vs 45%,\n                          <jats:italic>P<\/jats:italic>\n                          &lt; 0.001) were significantly less with gemcitabine.\n                        <\/jats:p>\n                      <\/jats:list-item>\n                      <jats:list-item>\n                        <jats:p>\n                          In a second trial of high\u2010risk patients the recurrence rate was significantly greater with gemcitabine compared with BCG (53.1% vs 28.1%,\n                          <jats:italic>P<\/jats:italic>\n                          = 0.04%) and the time to recurrence significantly shorter with gemcitabine (25.5 vs 39.4 months,\n                          <jats:italic>P<\/jats:italic>\n                          = 0.042).\n                        <\/jats:p>\n                      <\/jats:list-item>\n                      <jats:list-item>\n                        <jats:p>\n                          Finally, in a third trial of high\u2010risk patients who had failed previous intravesical BCG therapy, gemcitabine was associated with significantly fewer recurrences (52.5% vs 87.5%,\n                          <jats:italic>P<\/jats:italic>\n                          = 0.002) and a longer time to recurrence (3.9 vs 3.1 months,\n                          <jats:italic>P<\/jats:italic>\n                          = 0.9) compared with BCG. Progression rates were similar in both groups (33% vs 37.5%,\n                          <jats:italic>P<\/jats:italic>\n                          = 0.12) with no significant differences in grade 2 or 3 toxicities.\n                        <\/jats:p>\n                      <\/jats:list-item>\n                      <jats:list-item>\n                        <jats:p>The data from several observational studies confirm the pharmacology of gemcitabine as an intravesical agent whilst others report the activity of gemcitabine in terms of tumour recurrence. However, these studies are inherently biased and these data should be interpreted appropriately.<\/jats:p>\n                      <\/jats:list-item>\n                      <jats:list-item>\n                        <jats:p>In conclusion a single study suggests that in NMIBC multiple doses of intravesical gemcitabine reduce tumour recurrences to a greater extent than a single dose.<\/jats:p>\n                      <\/jats:list-item>\n                      <jats:list-item>\n                        <jats:p>In contrast, a single dose immediately after surgery is ineffective based on one study. Gemcitabine may be more active than MMC with a lower toxicity profile.<\/jats:p>\n                      <\/jats:list-item>\n                      <jats:list-item>\n                        <jats:p>Compared with intravesical BCG therapy, gemcitabine had similar effects in intermediate\u2010risk patients, less effective in high\u2010risk patients and superior in BCG\u2010refractory patients. However, each randomised trial identified represents a different clinical setting in NMIBC and therefore the evidence base is limited. Consequently these data should be interpreted with caution until further corroborative evidence becomes available.<\/jats:p>\n                      <\/jats:list-item>\n                      <jats:list-item>\n                        <jats:p>Intravesical gemcitabine is a promising drug that may add to the urologist's options in treating patients with NMIBC.<\/jats:p>\n                      <\/jats:list-item>\n                    <\/jats:list>\n                  <\/jats:p>","DOI":"10.1111\/j.1464-410x.2011.10880.x","type":"journal-article","created":{"date-parts":[[2012,2,7]],"date-time":"2012-02-07T08:55:57Z","timestamp":1328604957000},"page":"496-505","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":125,"title":["Intravesical gemcitabine therapy for non\u2010muscle invasive bladder cancer (NMIBC): a systematic review"],"prefix":"10.1111","volume":"109","author":[{"given":"Mike D.","family":"Shelley","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gabriel","family":"Jones","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anne","family":"Cleves","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Timothy J.","family":"Wilt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Malcolm D.","family":"Mason","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Howard G.","family":"Kynaston","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2012,2,7]]},"reference":[{"key":"e_1_2_8_2_2","doi-asserted-by":"publisher","DOI":"10.1080\/03008880802285032"},{"key":"e_1_2_8_3_2","doi-asserted-by":"publisher","DOI":"10.3322\/canjclin.57.1.43"},{"key":"e_1_2_8_4_2","unstructured":"Cancer Research UK.Bladder cancer statistics\u2010UK.2011. Available at:http:\/\/info.cancerresearchuk.org\/cancerstats\/types\/bladder. Accessed December 2011."},{"key":"e_1_2_8_5_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1464-410X.2011.10341.x"},{"key":"e_1_2_8_6_2","first-page":"454","volume-title":"Current Clinical Urology: Bladder Cancer","author":"Raj GV","year":"2010"},{"key":"e_1_2_8_7_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.eururo.2004.05.001"},{"key":"e_1_2_8_8_2","doi-asserted-by":"crossref","first-page":"839","DOI":"10.1016\/S0022-5347(18)33075-1","article-title":"Phase II trial of intravesical gemcitabine in BCG\u2010refractory transitional cell carcinoma of the bladder","volume":"175","author":"Dalbagni G","year":"2006","journal-title":"J Urol"},{"key":"e_1_2_8_9_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.urology.2004.08.027"},{"key":"e_1_2_8_10_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.urology.2005.04.062"},{"key":"e_1_2_8_11_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2008.20.8199"},{"key":"e_1_2_8_12_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.juro.2011.02.1765"},{"key":"e_1_2_8_13_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.eururo.2009.06.010"},{"key":"e_1_2_8_14_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.urology.2005.03.084"},{"key":"e_1_2_8_15_2","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.24914"},{"key":"e_1_2_8_16_2","doi-asserted-by":"publisher","DOI":"10.1159\/000273461"},{"key":"e_1_2_8_17_2","doi-asserted-by":"publisher","DOI":"10.1016\/S1569-9056(04)90480-0"},{"key":"e_1_2_8_18_2","doi-asserted-by":"publisher","DOI":"10.1016\/S1569-9056(05)80881-4"},{"key":"e_1_2_8_19_2","doi-asserted-by":"publisher","DOI":"10.1016\/S1569-9056(07)60147-X"},{"key":"e_1_2_8_20_2","doi-asserted-by":"publisher","DOI":"10.1200\/jco.2004.22.14_suppl.4685"},{"key":"e_1_2_8_21_2","first-page":"119","article-title":"Intravesical gemcitabine after transurethral resection in patients with superficial bladder cancer","volume":"15","author":"Iannelli A","year":"2004","journal-title":"Ann Oncol"},{"key":"e_1_2_8_22_2","first-page":"80","article-title":"Intravescical Gemcitabine therapy for superfical transitional cell carcinoma pTa\u2010T1 G degrees 1\/3 after transurethral resection","volume":"16","author":"De Cataldis G","year":"2005","journal-title":"Ann Oncol"},{"key":"e_1_2_8_23_2","first-page":"249","article-title":"A phase II study of intravesical gemcitabine as adjuvant therapy in patients (pts) with superficial bladder carcinoma: final results","volume":"3","author":"Bounedjar A","year":"2005","journal-title":"Eur Urol Suppl"},{"key":"e_1_2_8_24_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.eururo.2006.08.038"},{"key":"e_1_2_8_25_2","doi-asserted-by":"publisher","DOI":"10.1038\/sj.bjc.6604074"},{"key":"e_1_2_8_26_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.urolonc.2007.10.016"},{"key":"e_1_2_8_27_2","first-page":"1","article-title":"Multicenter study on the use of gemcitabine to prevent recurrence of multiple\u2010recurring superficial bladder tumors following intravesical antiblastic agents and\/or BCG: evaluation of tolerance","volume":"78","author":"Morabito F","year":"2006","journal-title":"Arch Ital Urol Androl"},{"key":"e_1_2_8_28_2","doi-asserted-by":"publisher","DOI":"10.1097\/CAD.0b013e3283324d83"},{"key":"e_1_2_8_29_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.urolonc.2008.11.019"},{"key":"e_1_2_8_30_2","doi-asserted-by":"crossref","first-page":"840","DOI":"10.1016\/S0022-5347(18)33076-3","article-title":"Intravesical sequential gemcitabine\u2010mitomycin chemotherapy as salvage treatment for patients with refractory superficial bladder cancer","volume":"175","author":"Maymi JL","year":"2006","journal-title":"J Urol"},{"key":"e_1_2_8_31_2","doi-asserted-by":"publisher","DOI":"10.1159\/000090870"},{"key":"e_1_2_8_32_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2003.09.028"},{"key":"e_1_2_8_33_2","doi-asserted-by":"publisher","DOI":"10.1016\/S1569-9056(04)90479-4"},{"key":"e_1_2_8_34_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.eururo.2003.09.014"},{"key":"e_1_2_8_35_2","first-page":"2493","article-title":"Intravesical gemcitabine in superficial bladder cancer: a phase II safety, efficacy and pharmacokinetic study","volume":"25","author":"Mattioli F","year":"2005","journal-title":"Anticancer Res"},{"key":"e_1_2_8_36_2","doi-asserted-by":"publisher","DOI":"10.1159\/000089164"},{"key":"e_1_2_8_37_2","first-page":"940","article-title":"Plasma pharmacokinetics of gemcitabine after intravesical administration","volume":"46","author":"Codacci\u2010Pisanelli G","year":"2005","journal-title":"Proc Am Assoc Cancer Res"},{"key":"e_1_2_8_38_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.urology.2009.05.094"},{"key":"e_1_2_8_39_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1464-410X.2010.09496.x"},{"key":"e_1_2_8_40_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ctrv.2009.12.005"},{"key":"e_1_2_8_41_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1464-410X.2003.04655.x"},{"key":"e_1_2_8_42_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1464-410x.2001.02306.x"},{"key":"e_1_2_8_43_2","first-page":"27","article-title":"Pharmacogenetics determinants of anticancer activity of intravesical gemcitabine in patients with superficial transitional cell carcinoma of the bladder","volume":"47","author":"De Braud F","year":"2006","journal-title":"Proc Am Assoc Cancer Res"}],"container-title":["BJU International"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fj.1464-410X.2011.10880.x","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/bjui-journals.onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/j.1464-410X.2011.10880.x","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,29]],"date-time":"2025-10-29T11:12:04Z","timestamp":1761736324000},"score":1,"resource":{"primary":{"URL":"https:\/\/bjui-journals.onlinelibrary.wiley.com\/doi\/10.1111\/j.1464-410X.2011.10880.x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2012,2]]},"references-count":42,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2012,2]]}},"alternative-id":["10.1111\/j.1464-410X.2011.10880.x"],"URL":"https:\/\/doi.org\/10.1111\/j.1464-410x.2011.10880.x","archive":["Portico"],"relation":{},"ISSN":["1464-4096","1464-410X"],"issn-type":[{"value":"1464-4096","type":"print"},{"value":"1464-410X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2012,2]]},"assertion":[{"value":"2012-02-07","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}